PRLX Insider Trading Activity and SEC Form 4 Filings
PRLX insider trading summary
No open-market insider purchases or sales of Parallax Health Sciences, Inc. (PRLX) have been reported on SEC Form 4 in the past 12 months.
Latest PRLX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 31, 2019 | Paul R Arena | CEO, President | Buy | $100K (2,000,000 @ $0.05) |
| Dec 31, 2019 | Calli Bucci | CFO, Secretary | Buy | $100K (2,000,000 @ $0.05) |
| Sep 30, 2019 | Paul R Arena | CEO, President | Buy | $100K (1,600,000 @ $0.06) |
| Sep 30, 2019 | Calli Bucci | CFO, Secretary | Buy | $100K (1,600,000 @ $0.06) |
| Sep 30, 2019 | Nathaniel T Bradley | Chief Technology Officer | Buy | $100K (1,600,000 @ $0.06) |
| Sep 30, 2019 | John L Ogden | Director | Buy | $75K (1,200,000 @ $0.06) |
| Apr 6, 2018 | Paul R Arena | President | Buy | $3K (2,500,000 @ $0.00) |
| Apr 5, 2018 | Calli Bucci | CFO | Buy | $5K (5,000,000 @ $0.00) |
| Apr 5, 2018 | John L Ogden | Director | Buy | $500 (500,000 @ $0.00) |
| Apr 5, 2018 | Edward W. Withrow Jr | Director | Buy | $500 (500,000 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.